|
Market Closed -
Other stock markets
|
Pre-market 08:58:22 | |||
| 154.21 USD | -0.15% |
|
156.52 | +1.50% |
| 08-05 | Sandoz gains on strong biosimilar growth, touts 'golden decade' | RE |
| 08-03 | Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31 | DJ |
| Market Cap | 293B 254B 238B 218B 411B 27,892B 416B 2,784B 1,092B 13,936B 1,099B 1,075B 46,385B | P/E 2026 * |
21.9x | P/E 2027 * | 18.7x |
|---|---|---|---|---|---|
| Enterprise Value | 326B 283B 265B 242B 457B 31,047B 463B 3,098B 1,216B 15,512B 1,224B 1,197B 51,630B | EV / Sales 2026 * |
5.66x | EV / Sales 2027 * | 5.25x |
| Free-Float |
91.66% | Yield 2026 * |
2.83% | Yield 2027 * | 2.96% |
Last Transcript: Novartis AG
| 1 day | +1.51% | ||
| 1 week | -2.67% | ||
| Current month | -1.24% | ||
| 1 month | -0.82% | ||
| 3 months | +3.94% | ||
| 6 months | -1.41% | ||
| Current year | +11.85% |
| 1 week | 152.99 |  | 156.37 |
| 1 month | 149.33 | | 160.34 |
| Current year | 135.55 | | 170.46 |
| 1 year | 115.75 | | 170.46 |
| 3 years | 92.19 | | 170.46 |
| 5 years | 74.09 | | 170.46 |
| 10 years | 66.93 | | 170.46 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2018-01-31 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 2026-03-15 |
Karen Hale
CMP | Compliance Officer | 58 | 2025-04-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 2014-12-31 |
| Director/Board Member | 69 | 2015-12-31 | |
Ton Büchner
BRD | Director/Board Member | 61 | 2015-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.15% | -2.67% | - | - | 293B | |
| +1.89% | +3.20% | +59.70% | +165.18% | 1,062B | |
| -0.24% | +0.45% | +50.64% | +52.02% | 619B | |
| -0.95% | -5.26% | +24.23% | +65.08% | 431B | |
| +1.74% | +5.15% | +49.26% | +40.38% | 358B | |
| +0.96% | +0.06% | +36.14% | +40.99% | 293B | |
| +1.22% | -5.02% | +9.57% | +10.21% | 247B | |
| -0.73% | +4.44% | +42.22% | +66.41% | 219B | |
| +3.76% | -0.64% | -1.39% | -44.19% | 200B | |
| -0.68% | -0.32% | +18.66% | +66.32% | 162B | |
| Average | +0.99% | -1.90% | +32.11% | +51.38% | 399.14B | |
| Weighted average by Cap. | +0.72% | -0.83% | +41.15% | +78.28% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.58B 49.97B 46.79B 42.8B 80.81B 5,485B 81.86B 547B 215B 2,741B 216B 212B 9,122B | 61.12B 53.04B 49.67B 45.43B 85.77B 5,823B 86.89B 581B 228B 2,909B 229B 225B 9,683B |
| Net income | 13.78B 11.96B 11.2B 10.24B 19.34B 1,313B 19.59B 131B 51.41B 656B 51.74B 50.62B 2,183B | 15.36B 13.33B 12.48B 11.42B 21.55B 1,463B 21.83B 146B 57.3B 731B 57.66B 56.41B 2,433B |
| Net Debt | 33.11B 28.74B 26.91B 24.61B 46.47B 3,154B 47.08B 315B 124B 1,576B 124B 122B 5,246B | 27.82B 24.14B 22.6B 20.68B 39.04B 2,650B 39.54B 264B 104B 1,324B 104B 102B 4,407B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-06 | US$154.21 | -0.15% | 1,045,448 |
| 26-08-05 | US$154.44 | +0.76% | 1,177,802 |
| 26-08-04 | US$153.27 | -0.26% | 1,706,548 |
| 26-08-03 | US$153.67 | -1.59% | 1,666,572 |
| 26-07-31 | US$156.15 | -1.45% | 1,546,279 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
- NVS Stock
Select your edition
All financial news and data tailored to specific country editions
